Page last updated: 2024-08-22

tiletamine hydrochloride and Lymphoma, Primary Effusion

tiletamine hydrochloride has been researched along with Lymphoma, Primary Effusion in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dabaghmanesh, N; Horie, R; Ishida, T; Katano, H; Matsubara, A; Miyake, A; Nakano, K; Umezawa, K; Watanabe, T	1

Other Studies

1 other study(ies) available for tiletamine hydrochloride and Lymphoma, Primary Effusion

Article	Year
Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer science, 2009, Volume: 100, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 8; Caspase 9; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexanones; Dose-Response Relationship, Drug; Enzyme Activation; HeLa Cells; Herpesvirus 8, Human; Humans; In Situ Nick-End Labeling; Jurkat Cells; K562 Cells; Lymphoma, Primary Effusion; NF-kappa B; Time Factors	2009

Article

Year

Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.

Cancer science, 2009, Volume: 100, Issue:4

Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 8; Caspase 9; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexanones; Dose-Response Relationship, Drug; Enzyme Activation; HeLa Cells; Herpesvirus 8, Human; Humans; In Situ Nick-End Labeling; Jurkat Cells; K562 Cells; Lymphoma, Primary Effusion; NF-kappa B; Time Factors

2009